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Abstract
Background: There has been much interest in targeting intracellular redox pathways as a therapeutic approach for cancer.
Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell
behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols.
Methodology/Principal Findings: To test this hypothesis, we used the sesquiterpene lactone parthenolide, a known anti-
cancer agent. Using flow cytometry, and western blotting to label free thiols with Alexa Fluor 633 C5 maleimide dye and N-
(biotinoyl)-N-(iodoacetyl) ethylendiamine (BIAM), respectively, we show that parthenolide decreases the level of free
exofacial thiols on Granta mantle lymphoma cells. In addition, we used immuno-precipitation techniques to identify the
central redox regulator thioredoxin, as one of the surface protein thiol targets modified by parthenolide. To examine the
functional role of parthenolide induced surface protein thiol modification, we pretreated Granta cells with cell impermeable
glutathione (GSH), prior to exposure to parthenolide, and showed that GSH pretreatment; (a) inhibited the interaction of
parthenolide with exofacial thiols; (b) inhibited parthenolide mediated activation of JNK and inhibition of NFkB, two well
established mechanisms of parthenolide activity and; (c) blocked the cytotoxic activity of parthenolide. That GSH had no
effect on the parthenolide induced generation of intracellular reactive oxygen species supports the fact that GSH had no
effect on intracellular redox. Together these data support the likelihood that GSH inhibits the effect of parthenolide on JNK,
NFkB and cell death through its direct inhibition of parthenolide’s modulation of exofacial thiols.
Conclusions/Significance: Based on these data, we postulate that one component of parthenolide’s anti-lymphoma activity
derives from its ability to modify the redox state of critical exofacial thiols. Further, we propose that cancer cell exofacial
thiols may be important and novel targets for therapy.
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Introduction
There has been much recent interest in targeting intracellular redox
signaling pathways as a therapeutic approach for cancer [1–3]. An
integral component of these pathways is the thiol-disulfide oxidore-
duction system whereby the function of proteins which contain free
thiol groups (-SH) in their active or regulatory sites (i.e. transcription
factors, molecular adapters, chaperones, protein tyrosine phosphatases
and proteases) are regulated, in part, by thiol-disulfide oxidoreduction,
often mediated through the thioredoxin-thioredoxin reductase and
glutaredoxin-glutathione systems [4]. Finally, the activity of several
anti-cancer agents, such as suberoylanilide hydroxamic acid (SAHA)
and curcumin,are thought to workin part by modulating this pathway,
inhibiting thioredoxin and thioredoxin reductase, respectively [5,6].
Whereas there is much data to support the critical role that
thiol-disulfide oxidoreduction plays in the regulation of intracel-
lular processes, emerging data also suggests that cell surface
protein thiols (i.e. exofacial thiols) are targets of redox regulation
and that the redox status of such thiols regulates critical cellular
functions. For example, the redox status of exofacial thiols on T-
cells regulates their activation and proliferation [7]. Indeed, the
redox status of critical thiols on the immunoglobulin superfamily
member CD4, regulates both T-cell binding to antigen presenting
cells as well as HIV-1 entry into CD4
+ T-cells [8]. In fact, the
levels of free exofacial thiols on normal donor lymphocytes differ
from that seen from patients with HIV [9,10]. In addition, the
thiol redox status of integrin a-4 affects integrin-mediated cell
adhesion [11]. Similarly, the thiol redox status of the tumor
necrosis factor receptor superfamily member 8 (TNFRSF8/CD30)
influences whether this receptor can engage its cognate ligand and
transduce its downstream signaling in lymphocytes [12]. Finally
various membrane receptors, ion channels [13] and extracellular
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We therefore hypothesized that anti-cancer therapies may
modulate the redox state of cancer cell exofacial thiols.
Parthenolide, a plant derived sesquiterpene lactone, has shown
significant antitumor effects against human acute myeloid
leukemia (AML) [15], acute and chronic lymphocytic leukemia
(CLL) [16], and such solid tumors as breast [17], cholangiocarci-
noma [18] and pancreatic cancer [19]. As a sesquiterpene lactone,
it contains unsaturated double bonds conjugated with a carbonyl
group (O=C–C=CH2) having nucleophilic properties which
would be anticipated to react with free protein thiols via a Michael-
like addition [20]. Therefore, we determined whether parthenolide
modulates the redox state of lymphoma cell exofacial thiols.
Materials and Methods
Cell Culture and Chemical Reagents
All chemical reagents were purchased from Sigma (St. Louis,
MO) unless otherwise stated. The human diffuse large B-cell
lymphoma lines, SUD-HL6 [21] and OCI-LY19 [22], and the
mantle cell lymphoma lines Granta [23], HF4B [24] and Rec-1
[25] were cultured as described [26]. The DLCL27B primary line
(obtained from patient biopsy under a University of Rochester
Institutional Review Board – approved protocol, was kindly
provided by Randall Rossi, University of Rochester; informed
consent was obtained in accordance with Declaration of Helsinki)
was cultured in IMDM supplemented with 10% human plasma.
All cells were maintained and treated at 37u and 5% CO2 unless
otherwise noted. All cells were determined to be mycoplasma free
using the MycoAlertH Mycoplasm Detection Kit (Lonza, Rock-
land, ME).
Cell Viability Assay
Cells were treated with varying concentrations of parthenolide
for 24 h and an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay was then performed as described [26].
The results are presented as the percentage of cells that reduce
MTT, as compared to DMSO-treated control cells. The
interaction between parthenolide and MTT was tested, and no
change in the absorbance of MTT was observed as a result of the
addition of parthenolide in a cell free system (data not shown).
Measurements of Reactive Oxygen Species Generation
Granta cells (10
6/ml) were treated with antioxidant or vehicle for
1.5 h, stained with H2DCFDA (10 mM) (Invitrogen, Carlsbad, CA),
treated with parthenolide (30 mM) or vehicle for an additional 15 to
30 min and then acquired on a 5-color upgraded FACScan
cytometer (Becton-Dickinson, San Diego, CA and Cytek Develop-
m e n t ,F r e m o n t ,C A ) .H 2DCFDA staining intensity was determined
using FlowJo software version 7.2.4 (Tree Star, Ashland, OR).
Cell Surface Free Thiol Measurements
Granta cells (10
6/ml) were treated with antioxidant or vehicle
for 2 h then exposed to parthenolide (30 mM) for an additional
3 h. Free surface thiol groups were determined using the Alexa
Fluor 633 C5 maleimide dye (Invitrogen, Carlsbad, CA) as
described [9]. Cells were acquired on a FACScan cytometer and
analyzed using FlowJo software as above.
Determination of Plasma Membrane Associated
Thioredoxin
Granta cells were surface stained with a rabbit anti-thioredoxin
primary antibody (dilution 1:200 in PBS containing 1% FBS
(PBS/FBS); Abcam, Cambridge, MA) followed by an Alexa Fluor
633 conjugated anti-rabbit secondary antibody (dilution 1:200 in
PBS/FBS; Invitrogen, Carlsbad, CA). Stained cells were harvested
and acquired on a FACScan cytometer and analyzed using FlowJo
software.
Determination of Cell Surface Protein Thiols with BIAM
Granta cells (10
6/ml) were treated with antioxidants or vehicle
for 2 h followed by treatment with parthenolide (10 or 30 mM) or
H2O2 (100 mM) for 3 h, followed by treatment with 100 mM
BIAM (Invitrogen, Carlsbad, CA) as described [11]. A plasma
membrane enriched fraction, obtained as described [9], was
resolved by 15% SDS-PAGE (minimum of 20 mg of protein)
transferred to a nitrocellulose membrane (BioRad, Hercules, CA)
and probed with streptavidin-peroxidase (dilution 1:2000; Sigma,
St. Louis, MO) or specific antibodies. Purity of the plasma
membrane enriched fractions was determined by western blot
analysis using an anti-transferrin antibody (Zymed Lab. Invitro-
gen, Carlsbad, CA).
PEGylation of Thioredoxin
Human, recombinant, N-terminal histidine tagged thioredoxin
(Trx; <14kDa; 50 mg) was incubated with parthenolide (at the
concentrations indicated in the legend to figures) for 30 min
followed by incubation with MM(PEG)24 (150 mM; Pierce Biotech.,
Rockford, IL) for 30 min. The samples were then resolved by 17%
SDS-PAGE, transferred to a nitrocellulose membrane (BioRad,
Hercules, CA) and probed with rabbit anti-thioredoxin primary
antibody (dilution 1:200; Abcam, Cambridge, MA).
Immunoprecipitation
Plasma membrane enriched cellular fractions from Granta cells
(see Determination of Cell Surface Protein Thiols with BIAM
section), were incubated in RIPA buffer, supplemented with 1 mM
PMSF and Na3VO4, for 15 min followed by centrifugation.
Supernatants were incubated with a 50% slurry of neutravidin-
agarose (Pierce Biotech., Rockford, IL) as described [27] and the
samples were resolved by 15% SDS-PAGE, transferred to a
nitrocellulose membrane (BioRad, Hercules, CA) and probed
against thioredoxin as above. To determine relative protein
amount, a parallel electrophoresis was prepared, where the gel was
stained with Coomassie Blue (data not shown).
NFkB and JNK Determination
For detection of NFkB, JNK, and IkB-a (both phosphorylated
and total), Granta cells were treated with GSH (5 mM) or vehicle
for 2 h followed by treatment with parthenolide (30 mM) for 3 h.
Treated cells were lysed with a buffer containing 10 mM HEPES,
1.5 mM MgCl2, 10 mM DTT, 0.5 mM PMSF and 0.1% NP-40
supplemented with a protease inhibitor cocktail (pH 7.9; Calbio-
chem, San Diego, CA). Proteins (20 mg) were resolved by 15% or
8% SDS-PAGE, transferred to a nitrocellulose membrane (BioRad,
Hercules, CA) and probed with anti-phospho-NFkB p65 (dilution
1:100; Cell Signaling, Danvers, MA), anti-NFkB p65 (dilution
1:100; Cell Signaling, Danvers, MA), or anti-phospho-SPK/JNK
(dilution 1:100; Cell Signaling, Danvers, MA) rabbit polyclonal
antibodies, anti-phospho-IkB-a (dilution 1:100; Abcam, Cam-
bridge, MA) or anti-IkB-a (dilution 1:100; Santa Cruz Biotech,
Santa Cruz, CA) rabbit polyclonal antibodies or, as a loading
control, a mouse anti-actin antibody (dilution 1:5,000; Calbiochem,
San Diego, CA). Blots were detected with goat anti-rabbit or anti-
mouse polyclonal antibodies conjugated with horseradish peroxi-
dase (dilution 1:10,000; Santa Cruz Biotech, Santa Cruz, CA).
Parthenolide and Surface -SH
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For determination of NFkB activation, Granta cells (3610
7)
were treated with GSH (5 mM) or vehicle for 2 h followed by
treatment with parthenolide (30 mM) for 3 h. Nuclear extracts
from the cells were prepared and p65 DNA binding activity was
measured using the TransAM
TM NFkB kit according to the
manufacturer’s instructions (Active Motif, Carlsbad, CA).
Statistical Analysis
The unpaired Student’s t-test was used to determine the
statistical difference between experimental and control groups. P
values ,0.05 were considered significant.
Results
Parthenolide Treatment Results in a Dose-Dependent
Decrease in Lymphoma Cell Viability
To determine the effect of parthenolide on mantle cell
lymphoma (MCL) and diffuse large B-cell lymphoma (DLCL)
viability, MTT assays were performed after 24 h exposure of
MCL and DLCL cells to increasing doses of parthenolide. As
shown in Fig. 1A, the viability of Granta, Rec-1 and HF4B cells
(MCL cell lines) decreased in a dose-dependent fashion after
exposure to parthenolide, with an EC50 of 7.560.2, 5.360.2 and
5.260.3 mM, respectively. Parthenolide similarly decreased the
viability of the DLCL cell lines SUD-HL6 and OCI-Ly19, with an
EC50 of 9.360.4 and 7.360.3 mM, respectively, (Fig. 1B).
Parthenolide also had a potent dose-dependent effect on the
viability of DLCL cells cultured directly from a patient biopsy
specimen (DLCL 27B) having an EC50=3.060.11 mM (Fig. 1B).
In our subsequent studies, we used the Granta MCL line to
elucidate the mechanism of parthenolide action.
Parthenolide Attenuates the Levels of Exofacial Free
Thiols as Assessed by Flow Cytometry
To directly assess the effect of parthenolide on Granta cell
exofacial thiols we used an Alexa Fluor 633 coupled maleimide
compound (ALM). Maleimide is a nucleophile that covalently
binds to free thiol groups, and when coupled with the charged
Alexa Fluor 633 dye becomes cell impermeable, allowing for the
examination of cell surface thiol levels. As shown in Fig. 2,
exposure of Granta cells to 30 mM parthenolide for 3 h resulted in
a decrease in exofacial free thiols by approximately 36% relative to
that of vehicle treated control cells. In contrast, treatment with
cell-impermeable glutathione (GSH) increased the levels of
exofacial free thiols by approximately 49% (Fig. 2). When cells
were pretreated with GSH for 2 h, washed and exposed to 30 mM
parthenolide for 3 h there was no parthenolide induced decrease
in exofacial free thiol levels (Fig. 2). Pretreatment with the cell
permeable monoethyl ester (GSHee) or the GSH precursor N-
acetyl-L-cysteine (NAC) similarly protected exofacial thiols from
modification by parthenolide (data not shown). The histogram
shown in Fig. 2 is representative of 3 independent experiments.
The MFI (mean fluorescent intensity) of the control cells from all 5
experiments varied only by +/2 8%, and the direction of each
experimental result in relationship to that of the control cells was
the same in each experiment. Taken together, the data suggest
that parthenolide modulates exofacial free thiol groups; a process
that is inhibited by pretreatment with GSH.
To control for the possibility that GSH pretreatment alters
intracellular redox, which would result in an increase in surface
free thiols, we evaluated the effect of GSH on parthenolide
induced ROS generation (Supplementary Fig. S1). Whereas
pretreatment for 2 h with 5 mM of cell permeable GSHee or
NAC partially inhibited parthenolide induced ROS generation, a
2 h pretreatment with 5 mM GSH had no effect on intracellular
ROS generation. Similar results were seen using parthenolide at
doses of 5 and 10 mM for 15, 30 and 60 min of exposure (data not
shown). If GSH was altering intracellular redox it should have
attenuated parthenolide induced ROS generation similar to that
seen with GSHee and NAC. Taken together, these data suggest
that the effect of GSH on exofacial free thiols is a direct effect and
not due to an effect on intracellular redox.
To control for the possibility that exofacial thiol modification is
a result of intracellular H2O2, generated by parthenolide, which
would be anticipated to diffuse across the cell membrane and
directly modify exofacial thiols, we used the cell impermeable
H2O2 scavenger, catalase. Exposure of Granta cells to 5 mM
H2O2 resulted in exofacial protein oxidation, (as demonstrated by
Alexa Fluor staining; Supplemental Fig. S2A), which is blocked by
500 mM catalase. In contrast, exposure of Granta cells to 30 mM
parthenolide results in exofacial protein oxidation, which is not
blocked by catalase (Supplemental Fig. S2B). Taken together,
parthenolide is not modifying exofacial thiols through an H2O2
dependent mechanism.
Figure 1. Parthenolide treatment results in a dose-dependent
decrease in lymphoma cell viability. (A) Granta, Rec-1 and HF4B
mantle cell lymphoma cells or (B) DLCL 27B, SUD-HL6 and OCI-LY19
diffuse large cell lymphoma cells were treated with the indicated
concentrations of parthenolide for 24 h and cell viability measured by
MTT assay. The results are expressed as mean 6 s.d. (n=6).
doi:10.1371/journal.pone.0008115.g001
Parthenolide and Surface -SH
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To further confirm that parthenolide modifies exofacial free
thiols, we used a biotinylated thiol reactive reagent, N-(biotinoyl)-N-
(iodoacetyl) ethylendiamine (BIAM), which binds to free thiol
groups and is detected by streptavidin-peroxidase staining of
western blots. As shown in Fig. 3, lane 1, plasma membrane
enriched cell lysates from untreated Granta cells contain significant
numbers of proteins having free thiol groups (with each band
corresponding to a protein having a free thiol group able to interact
with BIAM). After exposure of Granta cells to 10 (Fig. 3, lane 2)o r
30 mM (Fig. 3, lane 3) parthenolide for 3 h, however, there is a dose
dependent decrease in the intensity of the bands corresponding to
,22kD and ,12kD suggesting that parthenolide is modifying the
free thiols of these proteins, making them unreactive to BIAM.
We next determined whether the cell impermeable GSH
attenuated the effect of parthenolide on the free thiols of the
,22 and,12kD proteins. Treatment of Granta cells with 5 mM
GSH alone (Fig. 3, lane 4) had no significant effect on the intensity
of the bands corresponding to the ,22 and ,12kD proteins as
compared to that seen in untreated control cells (Fig. 3, lane 1). In
contrast, a 2 h pre-treatment with 5 mM GSH followed by
exposure to 30 mM parthenolide for 3 h significantly attenuates
the decrease in the intensity (and thus modification) of the bands
corresponding to the ,22 and ,12kD proteins seen with a 3 h
exposure of 30 mM parthenolide alone (compare Fig. 3 lane 3,
parthenolide alone, with lane 5, GSH plus parthenolide).
As a control for the oxidation of protein free thiols, H2O2 was
used. Exposure of Granta cells to H2O2 resulted in decreased
signals in multiple bands that included the ,22kD and ,12kD
bands (Fig. 3, lane 6) modified by parthenolide. Equal protein
loading in each lane was demonstrated with actin staining.
Membrane purity is shown by blotting with an anti-transferrin
antibody (Supplementary Fig. S3). Taken together with the flow
cytometric data presented in Fig. 2, parthenolide modulates
exofacial free thiols, including those of proteins having molecular
weights of ,22kD and ,12kD, and such modifications are
blocked by pretreatment with GSH.
Identification of Surface Thioredoxin-1 as One of the
Targets of Parthenolide
We hypothesized that one of the candidate proteins modified by
parthenolide was thioredoxin-1, a 12kD protein containing thiol
groups amenable to parthenolide modification. We first evaluated
whether thioredoxin-1 can be detected on the Granta cell surface.
Granta cells were stained with an anti-thioredoxin antibody and
analyzed by flow cytometry (Fig. 4A). The mean fluorescent
Figure 2. Parthenolide attenuates the levels of exofacial free
thiols as assessed by flow cytometry. The change in Granta cell
free exofacial thiol groups was assessed by staining cells with 1 mM
Alexa 633 maleimide with analysis by flow cytometry after exposure to;
30 mM parthenolide alone for 3 h; 5 mM GSH alone for 2 h; 5 mM GSH
for 2 h followed by 30 mM parthenolide for 3 h; or no treatment
(control).
doi:10.1371/journal.pone.0008115.g002
Figure 3. Parthenolide attenuates the levels of exofacial free
thiols as assessed by western blot analysis. Plasma membrane
enriched cell lysates were obtained from Granta cells treated as follows:
(lane 1) untreated control cells; (lane 2)1 0mM parthenolide for 3 h;
(lane 3)3 0mM parthenolide for 3 h; (lane 4) 5 mM GSH alone for 2 h;
(lane 5) 5 mM GSH for 2 h followed by 30 mM parthenolide for 3 h; (lane
6) 100 mMH 2O2 for 3 h. The lysates were stained with the thiol probe
BIAM and blotted with streptavidin-HRP. As a protein loading control
the blots were also probed for actin (bottom panel).
doi:10.1371/journal.pone.0008115.g003
Parthenolide and Surface -SH
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approximately 85% greater than that of the secondary antibody
alone, confirming that thioredoxin is on the Granta cell surface.
We next determined whether parthenolide could directly
interact with free thiol groups within purified human thior-
edoxin-1. Thioredoxin-1 was co-incubated with maleimide
conjugated to a polyethylene glycol spacer having terminal methyl
groups (MM(PEG)24). Maleimide binds to free thiols on thior-
edoxin and upon SDS-PAGE separation and blotting with an anti-
thioredoxin antibody gives a characteristic ladder pattern which is
a mixture of thioredoxin with different molecular weights due to
MM(PEG)24 conjugation to $1 of the 4 free thiols of thioredoxin
(Fig. 4B, lane 2). However, when thioredoxin was pre-incubated
with different concentrations of parthenolide (ranging from 5 to
50 mM), the sites available for MM(PEG)24 disappeared in a dose
dependent manner (as evidenced by a decrease in laddering;
Fig. 4B, lanes 325), and were completely abolished in the presence
of 50 mM parthenolide (Fig. 4B, lane 6). Taken together,
parthenolide directly binds to free thiol groups on thioredoxin-1.
As expected, co-incubation of thioredoxin-1 with the thiol
alkylator, N-ethylmaleimide (NEM), also reduced the sites
available for MM(PEG)24 binding thus decreasing thioredoxin
laddering (Fig. 4B, lane 7).
Finally, we determined whether parthenolide was directly
modifying membrane associated thioredoxin-1 in Granta cells by
BIAM staining and neutravidin pull-down. As shown in Fig. 4C,
lane 1, one of the biotinylated proteins pulled down by neutravidin
is thioredoxin. However, when Granta cells were treated with
30 mM parthenolide for 3 h, and then treated with BIAM, none of
the proteins pulled down by neutravidin reacted with the anti-
thioredoxin antibody (Fig. 4C, lane 2), suggesting that parthenolide
has modified thioredoxin free thiols, making them unavailable to
BIAM binding and thus they are not pulled-down by neutravidin.
In contrast, when cells were first treated with 5 mM GSH for 2 h,
and then exposed to 30 mM parthenolide for 3 h, the pulled down
proteins were recognized by the anti-thioredoxin antibody (Fig. 4C,
lane 4), suggesting that the free thiol groups were protected from
parthenolide (via an as yet unknown mechanism), and thus
available for interaction with BIAM. Lastly, GSH treatment alone
had no effect on the thioredoxin pull-down (Fig. 4C, lane 3).
To exclude the possibility that the effect of parthenolide on
thioredoxin free thiols was an indirect effect, due to a change in
the pH of the buffer elicited by parthenolide (and the thiol
modifications thus due to the change in pH), we evaluated the pH
in the buffer, in the presence and absence of parthenolide, with
both color pH indicator strips and a pH meter. Parthenolide had
no effect on the pH of the buffer (data not shown).
Parthenolide Cytotoxicity Is Blocked by Thiol
Antioxidants
To gain insight into whether the parthenolide induced
reduction in free exofacial thiols is a mechanism through which
parthenolide mediates its cytotoxic effect, we next determined
whether the effect of parthenolide on Granta cell death can be
blocked by pretreatment with GSH, GSHee and NAC using the
same conditions that blocked the parthenolide induced decrease in
exofacial free thiols. As parthenolide can form covalent adducts
directly with GSH and NAC (data not shown), the antioxidants
were extensively washed out prior to the addition of parthenolide.
Figure 4. Identification of surface thioredoxin-1 as one of the
targets for parthenolide. (A) Granta cells were surface stained for
thioredoxin-1 and labeled with secondary antibody (anti-thioredoxin-1)
or incubated with secondary antibody alone (control), and subjected
to flow cytometric analysis. (B)H u m a np u r i f i e dt h i o r e d o x i n - 1( 1 4 k D ;
lane 1) was co-incubated with MM(PEG)24, without (lane 2)o rw i t h
pretreatment with 5 (lane 3), 10 (lane 4), 30 (lane 5)o r5 0 mM
parthenolide (lane 6). As a control for free thiol group specific staining,
thioredoxin-1 was pretreated with 10 mM of the thiol alkylating agent
N-ethylmaleimide (NEM) prior to incubation with MM(PEG)24 (lane 7).
The samples were then blotted and probed with a thioredoxin-1
antibody. (C) BIAM labeled proteins from plasma membrane enriched
fractions were precipitated using neutravidin-agarose resins, which
have a strong affinity for biotinylated proteins. The following
conditions were tested on Granta cells; untreated (lane 1), treated
with 30 mM parthenolide for 3 h (lane 2), 5 mM GSH for 2 h (lane 3), or
with 5 mM GSH for 2 h and then 30 mM parthenolide for additional 3 h
(lane 4). The cells were stained with BIAM and proteins having reduced
thiol groups were precipitated with Neutravidin-agarose and probed
with a thioredoxin-1 antibody. As a loading control (L.C.) the proteins
on the gel were stained with Coomassie blue and shown is the ,12kD
band.
doi:10.1371/journal.pone.0008115.g004
Parthenolide and Surface -SH
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parthenolide was sufficient to result in a significant decrease in cell
viability after 14 h (25% of control as measured by MTT assay),
although there was no significant cell death seen within the 3 h
duration of treatment itself (data not shown). When cells were
pretreated with thiol antioxidants for 2 h, the antioxidants washed
out, and the cells exposed to 30 mM parthenolide for 3 h, cell
viability increased from 25% without antioxidant pretreatment to
approximately 85% with 5 mM NAC, 5 mM GSEee or 5 mM
GSH pretreatment, respectively (Fig. 5). Similar results were seen
when the cells were exposed to 10 mM parthenolide (data not
shown). In contrast, when Granta cells were pretreated with
parthenolide (10 or 30 mM) for 3 h followed by antioxidant
exposure, the cytotoxic effects of parthenolide were not inhibited
(data not shown).
NFkB Antagonism and JNK Activation by Parthenolide Is
Blocked by GSH
As parthenolide has been shown to induce malignant cell death
by inhibiting NFkB activation and/or activating JNK [15,17], we
next determined whether GSH, which blocked the effect of
parthenolide on exofacial thiols, could alter the effect of
parthenolide on NFkB and JNK.
Using a highly sensitive and specific ELISA-based assay that
detects only activated NFkB subunits [28], exposure of Granta
cells to 30 mM parthenolide for 3 hours resulted in an approxi-
mately 5-fold decrease in p65 DNA binding activity (Fig. 6A).
These inhibitory effects of parthenolide on p65 DNA binding
activity, however, were reversed by preincubating the cells with
5 mM GSH (Fig. 6A).
Since the post-translational modification of p65 often deter-
mines the transcriptional activity of this molecule, we next
evaluated the effect of parthenolide on the key phosphorylation
site, serine 536, within the p65 molecule. Exposure of Granta cells
to 30 mM parthenolide for 3 hours resulted in a significant
decrease in the phosphorylation state of p65 (Fig. 6B, lane 2) which
Figure 5. Parthenolide cytotoxicity is blocked by pre-treatment
with thiol antioxidants. Where indicated, Granta cells were treated
with parthenolide alone for 3 h or with NAC (5 mM), GSHee (5 mM) or
GSH (5 mM) for 2 h, washed and then treated with 30 mM parthenolide
for an additional 3 h, and cell viability determined by MTT 11 h later.
*** p,0.05. The experimental points are the mean 6 s.d. of six
independent experiments.
doi:10.1371/journal.pone.0008115.g005
Figure 6. Parthenolide inhibition of NFkB and activation of JNK
is inhibited by GSH. (A)N F kB activity is inhibited by parthenolide as
assessed by TransAM NFkB kit (Active Motif). NFkB activation (measured
as OD450 nm and presented as % of that of the non-treated control
cells); of Granta cells treated with 30 mM parthenolide for 3 h; 5 mM
GSH alone; 5 mM GSH for 2 h followed by parthenolide 30 mM for 3 h.
(B–D) Western blot analysis of extracts from Granta cells; un-treated
(lane 1), treated with 30 mM parthenolide for 3 h (lane 2), 5 mM GSH
alone for 2 h (lane 3), and 5 mM GSH for 2 h, washed and treated with
30 mM parthenolide for additional 3 h (lane 4), using anti-phospho-
NFkB p65 (Ser536) or anti-NFkB (p65) rabbit Abs (B, upper and middle
panels, respectively); anti-phospho-IkB-a or anti-IkB-a rabbit Abs (C,
upper and middle panels, respectively); an anti-phospho-SPK/JNK
(Thr183/Tyr185) rabbit Ab or anti-SAPK/JNK mouse Ab (D, upper and
middle panels, respectively). As a protein loading control, blots were
probed for actin levels (B–D, bottom panels).
doi:10.1371/journal.pone.0008115.g006
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(Fig. 6B, lane 4). That the total p65 levels under these experimental
conditions remained unaltered suggests that the findings shown in
Fig. 6B are truly due to the modification of p65 by such
experimental conditions.
As the activation of NFkB is intimately coupled with the signal
induced phosphorylation and subsequent proteosomal degradation
of the NFkB inhibitor, IkB-a, we next evaluated the effect of
parthenolide on phospho- and total IkB-a levels. As shown in
Fig. 6C, exposure of Granta cells to 30 mM parthenolide for
3 hours resulted in a decrease in phospho-IkB-a, which is highly
consistent with the observed effects of parthenolide on p65 DNA
binding activity and modification of p65 (Fig. 6A, and 6B,
respectively). It is of interest that the levels of total endogenous
IkB-a were decreased in the cells exposed to GSH (Fig. 6C, lanes 3
and 4). This may be a result of the reported effects of GSH on IkB-
a degradation [29]
Finally the effect of GSH on parthenolide-mediated activation
of JNK was examined by conducting immunoblot analyses.
Analogous to the observations outlined in the above experiments,
parthenolide-dependent phosphorylation of JNK isoforms (p46
and p54) was completely blocked in the cells pre-treated with GSH
(Fig. 6D).
Discussion
The studies herein demonstrate that exposure of human mantle
and diffuse large cell lymphoma cells to parthenolide results in a
decrease in free exofacial thiols of proteins having molecular
weights of ,12kD and ,22kD. It is of interest that parthenolide
does not have a global effect on all free exofacial thiols but rather a
specific effect on exofacial thiols of these ,12 and ,22kD
proteins. Whether this is due, for example, to differences in the
protonation state of the different surface protein thiols and/or to
structural constraints of the proteins that alter the access
parthenolide has to the free thiols groups is not known.
We further identify the critical redox regulator thioredoxin-1 as
one such protein. In addition, we show that pretreatment of
Granta cells with cell impermeable GSH inhibits this parthenolide
induced decrease in exofacial thiols. We further show that GSH
inhibits parthenolide inhibition of NFkB and activation of JNK, as
well as parthenolide induced cell death. We therefore postulate
that one mechanism of the anti-lymphoma activity of parthenolide
may be modulation of exofacial thiols.
Alternative explanations for the above findings are that; (a)
despite extensive washout of GSH before exposure of Granta cells
to parthenolide, residual GSH binds to and prevents intracellular
accumulation of parthenolide and the subsequent elicitation of cell
death and; (b) GSH may result in an increase in intracellular GSH,
which itself would result in an increase in free exofacial thiols. If
either of these were true, however, then GSH pre-treatment of
Granta cells would be expected to inhibit parthenolide induced
ROS generation, which it does not (Supplementary Fig. S1).
It is also possible that the increased free surface thiols generated
by GSH pretreatment simply sequester parthenolide, preventing
its intracellular accumulation. If this was the case however, these
free thiol groups generated by GSH (which would bind the Alexa
Fluor 633 C5 maleimide dye and thus fluoresce) would be modified
by parthenolide (and would not bind the Alexa 633 maleimide and
thus not fluoresce), and as such the MFI of the GSH followed by
parthenolide treated cells would be less then that of the GSH alone
treated cells. In contrast, the level of free exofacial thiols after
exposure of cells to GSH followed by parthenolide is similar to that
seen after exposure of the cells to GSH alone (Fig. 2). How GSH
protects free exofacial thiols from modification by parthenolide is
not clear, but it may disrupt surface protein intra- and/or inter-
protein disulfide bonds, resulting in structural changes that make
the free thiol targets of parthenolide inaccessible to the drug.
The mechanism whereby altering the redox state of exofacial
thiols modulates intracellular events that result in cell death is not
clear. It is possible that surface thioredoxin, which we show is one
target of parthenolide, may mediate the cross-talk between
exofacial thiols and downstream intracellular events. For example,
thiol modification of surface thioredoxin results in its lipid raft-
mediated internalization resulting in changes in the intracellular
redox state [30]. Extracellular thioredoxin has also been shown to
regulate receptor-ligand signaling interactions, specifically the
binding of CD30 to its cognate ligand [12]. In addition, certain ion
channels (i.e. Ca
2+ channels) are activated as a result of the
disruption of extracellular disulfide bridges by thioredoxin [14].
Taken together, the effect of parthenolide on surface thioredoxin
may modulate intracellular pathways.
Parthenolide has been shown to have pre-clinical activity in
AML [15], CLL [16], as well as multiple solid tumors [17–19].
The effect of parthenolide is relatively tumor selective, having no
effect on normal hematopoietic stem cells or T-cells [15]. There
has been recent evidence to suggest that in contrast to the
oxidative extracellular redox state of normal cells, malignant cells
exist in a reduced extracellular environment [31]. This raises the
possibility that the tumor selectivity of parthenolide is due, in part,
to this difference in extracellular redox state. For example, it is
possible that the exofacial thiol targets of parthenolide are reduced
on cancer cells, and thus are free to interact with the drug, but are
oxidized on normal cells, thus unavailable for interaction with
parthenolide.
In summary, we show that parthenolide modulates cancer cell
exofacial thiols, including that of surface thioredoxin. That
blocking parthenolide modulation of such thiols also blocks
parthenolide induced cell death raises the possibility that one
mechanism for the anticancer activity of parthenolide is through
exofacial thiol modification. Indeed, the identification of such
targets of parthenolide, and a determination of whether these
targets differ in their redox status in normal compared to
malignant cells, will not only provide further insights into cancer
biology but will identify additional targets for development of
specific anti-cancer therapies.
Supporting Information
Figure S1 Generation of ROS in Granta cells as assessed by
H2DCFDA. The level of ROS in Granta cells after 15 min
exposure to 30 mM parthenolide was measured alone and after 2 h
preincubation with 5 mM GSHee (A), 5 mM GSH (B) and 5 mM
NAC (C). The results are representative of three independent
experiments. (C).
Found at: doi:10.1371/journal.pone.0008115.s001 (8.33 MB TIF)
Figure S2 The effect of parthenolide on exofacial free thiols is
not a consequence of H2O2 oxidation. (A) The change in Granta
cell free exofacial thiol groups was assessed by staining cells with
1 mM Alexa 633 malemide with analysis by flow cytometry after
exposure to 5 mM H2O2; 500 mM catalase (cat) and 5 mM
H2O2 for 3 h; and vehicle (control). (B) The change in Granta cell
free exofacial thiol groups was assessed as described above after
exposure to 30 mM parthenolide (pth) for 3 h; 500 mM catalase
(cat) and 30 mM parthenolide for 3 h; and vehicle (control). The
graphs are representative of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0008115.s002 (8.35 MB TIF)
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Samples corresponding to plasma membrane enriched fractions
(lane 1), and cytoplasmic fractions from Granta cells (lane 2), were
resolved by SDS-PAGE (20 mg of proteins), transferred and
probed against transferrin receptor (membrane protein) or actin.
Found at: doi:10.1371/journal.pone.0008115.s003 (8.52 MB TIF)
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